echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Immunity: control the brakes of the immune system to treat cancer and autoimmune diseases

    Immunity: control the brakes of the immune system to treat cancer and autoimmune diseases

    • Last Update: 2020-02-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    February 11, 2020 / BIOON / -- immunologists of Saint Judas children's research hospital found the key biological switch to control regulatory T-cells (specialized leukocytes that control the immune system)

    The relevant results were recently published in the Journal of immunology

    "Understanding the mechanisms that regulate T cells offers a range of options for drug development," said Dr

    Hongbo Chi, co-author of the Department of immunology at the University of Saint Jude

    "By increasing or inhibiting this activity at the right time, you can develop ways to treat cancer or autoimmune diseases

    "Image source: in their study, immunology tracked the molecular mechanism that controls a biological switch that activates regulatory T cells called mTORC1

    Until then, its mechanism has been a mystery

    Their study showed that two major regulators of mTORC1 are enzymes called rag and rheb

    When scientists found that rats lacking rag or rheb had a fatal autoimmune disease, they found the enzyme's key role in activating protective regulatory T cells

    In autoimmune diseases such as lupus erythematosus and rheumatoid arthritis, regulatory T cells are essential to prevent the immune system from attacking its own tissues

    The discovery of the mechanism of action of rag and rheb is important because drugs that activate these enzymes may prove useful in the treatment of autoimmune diseases

    These drugs will enhance the function of regulatory T cells as immune safety brakes

    This finding may also affect the effectiveness of enhanced immunotherapy for cancer

    In this treatment, the patient's own immune system is activated to target the tumor

    An important obstacle of this therapy is the immunosuppressive activity of regulatory T cells

    Drugs that inhibit rag or rheb can help cancer immunotherapy by inhibiting regulatory T cells

    The researchers found that amino acids play an important role in activating mTORC1 in regulatory T cells, which is mediated by rag and rheb

    Amino acids are part of the protein, which means that the "nutritional perception" of the immune system, such as the food a person eats, can affect that person's immune response - not only to cancer, but also to organ transplants and infections

    Reference: Hao Shi et al, amino acids license kinse mTORC1 activity and Treg cell function via small G proteins rag and rheb, immunity (2019)

    Doi: 10.1016/j.immunity.2019.10.001
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.